Nerve conduction impairment in experimental diabetes—proximodistal gradient of severity
Jyoti Patel BSc
Department of Pharmacology, St. Bartholomews's and Royal London Hospital School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London, UK
Search for more papers by this authorCorresponding Author
David R. Tomlinson DSc
Division of Neuroscience, School of Biological Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
Division of Neuroscience, School of Biological Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UKSearch for more papers by this authorJyoti Patel BSc
Department of Pharmacology, St. Bartholomews's and Royal London Hospital School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London, UK
Search for more papers by this authorCorresponding Author
David R. Tomlinson DSc
Division of Neuroscience, School of Biological Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
Division of Neuroscience, School of Biological Sciences, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UKSearch for more papers by this authorAbstract
We compared a conventional method of measurement of sciatic motor and sensory nerve conduction velocity, with a novel procedure that measures conduction in an 8-mm segment of the rat sural nerve. Conventional procedures gave reductions in velocity of 20% and 14% for motor and sensory fibers, respectively, whereas sural sensory fibers showed a 40% reduction (P <0.05). Changes were attenuated by treatment with either an aldose reductase inhibitor or a γ-linolenic acid–α-lipoic acid conjugate, such that values from conventional procedures were not significantly different from controls and the sural sensory deficit halved. Putative motor fibers of the sural nerve showed no conduction velocity deficit in diabetic rats. Measurement of chronaxie and rheobase in sural sensory fibers revealed mild reductions in excitability in diabetics, with prevention of the chronaxie change by the treatments. Thus, measurement of sensory conduction in distal nerve segments show more profound defects in diabetic rats and may give a truer picture of preventive drug efficacy. © 1999 John Wiley & Sons, Inc. Muscle Nerve 22: 1403–1411, 1999
REFERENCES
- 1Bostock H, Sears TA, Sherratt RM. The spatial distribution of excitability and membrane current in normal and demyelinated mammalian nerve fibers. J Physiol 1983; 341: 41–58. Medline
- 2Boulton AJM, Hardisty CA, Betts RP. Dynamic foot pressure and other studies as diagnostic and management aids in diabetic neuropathy. Diabetes Care 1983; 6: 26–33. Medline
- 3Bravenboer B, Kappelle AC, Van Buren T, Erkelens DW, Gispen WH. Acth4-9 analogue org 2766 can improve existing neuropathy in streptozotocin-induced diabetic rats. Acta Diabetol 1993; 30: 21–24. Medline
- 4Calcutt NA, Tomlinson DR, Willars GB. Ganglioside treatment of diabetic rats; effects on nerve adenosine triphosphatase activity and motor nerve conduction velocity. Life Sci 1988; 42: 1515–1520. Medline
- 5Cameron NE, Cotter MA, Horrobin DH, Tritschler HJ. Effects of a-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 1998; 41: 390–399. Medline
- 6Cameron NE, Cotter MA, Robertson S: The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Q J Exp Physiol 1989; 74: 917–926. Medline
- 7Cotter MA, Cameron NE. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 337–343. Medline
- 8Dyck PJ. Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy? N Engl J Med 1989a; 320: 57–60.
- 9Dyck PJ. Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg Lecture. Neurology 1989; 39: 111–118. Medline
- 10Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985; 108: 861–880. Medline
- 11Eliasson SG. Nerve conduction changes in experimental diabetes. J Clin Invest 1964; 43: 2353–2358.
- 12Fernyhough P, Gallagher A, Averill S, Priestley JV, Hounsom L, Patel J, Tomlinson DR. Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999; 48: 881–889. Medline
- 13Greene DA. Metabolic abnormalities in diabetic peripheral nerve: relation to impaired function. Metabolism 1983; 32: 118–123.
- 14Greene DA, De Jesus PV Jr, Winegrad AI. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975; 55: 1326–1336. Medline
- 15Greene DA, Stevens MJ, Feldman EL, Thomas TP. The DCCT, metabolism and diabetic neuropathy: perspectives for the fourth international symposium on diabetic neuropathy. Neurosci Res Commun 1997; 21: 1–4.
- 16Gregersen G. Diabetic neuropathy: influence of age, sex, metabolic control and duration of diabetes on motor conduction velocity. Neurology 1967; 17: 972–980. Medline
- 17Gregersen G. Variations in motor conduction velocity produced by acute changes of the metabolic state in diabetic patients. Diabetologia 1968; 4: 273–277.
Medline
10.1007/BF01309900 Google Scholar
- 18Harrison LM. Fiber diameter spectrum of the motor fibres of rat sural nerve. Exp Neurol 1975; 47: 364–366. Medline
- 19Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid congugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998; 41: 839–843. Medline
- 20Lambourne JE, Tomlinson DR, Brown AM, Willars GB. Opposite effects of diabetes and galactosaemia on ATPase activity in rat nervous tissue. Diabetologia 1987; 30: 360–362. Medline
- 21Low PA, Tuck RR, Dyck PJ, Schmelzer JD, Yao JK. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 1984; 81: 6894–6898. Medline
- 22Maeda K, Fernyhough P, Tomlinson DR. Effects of treatment of diabetic rats with human recombinant nerve growth factor on sciatic nerve conduction, Doppler flux and substance P levels. Diabet Nutr Metab 1997; 10: 3–8.
- 23Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 1983; 25: 433–438. Medline
- 24Mogyoros I, Kiernan MC, Burke D, Bostock H. Excitability changes in human sensory and motor axons during hyperventilation and ischaemia. Brain 1997; 120: 317–325. Medline
- 25Mïller-Felber W, Landgraf R, Scheuer R, Wagner S, Reimers CD, Nusser J, Abendroth D, Illner W-D, Land W. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation. Diabetes 1993; 42: 1482–1486. Medline
- 26Nakanishi T, Norris FH Jr. Motor fibers in rat sural nerve. Exp Neurol 1970; 26: 433–435. Medline
- 27Panizza M, Nilsson J, Roth BJ, Hallett M. Relevance of stimulus duration for activation of motor and sensory fibres: implications for the study of H reflexes and magnetic stimulation. Electroencephalogr Clin Neurophysiol 1992; 85: 22–29. Medline
- 28Redmond JMT, McKenna MJ, Feingold M, Ahmad BK. Sensory testing versus nerve conduction velocity in diabetic polyneuropathy. Muscle Nerve 1992; 15: 1334–1339. Medline
- 29Ruijten MWMM, De Haan G.-J., Michels RPJ, Pruijs-Brands A, Ongerboerde Visser BW, Verberk MM. Motor nerve refractory period distribution assessed by two techniques in diabetic polyneuropathy. Electroencephalogr Clin Neurophysiol 1994; 93: 306–311. Medline
- 30Schütt P, Muche H, Lehmann HJ. Refractory period impairment in sural nerves of diabetics. J Neurol 1983; 229: 113–119. Medline
- 31Sharma AK, Thomas PK. Peripheral nerve structure and function in experimental diabetes. J Neurol Sci 1974; 23: 1–15. Medline
- 32Suzuki K, Saito N, Sakata Y, Toyota T, Goto Y. A new prostaglandin E1 analogue (TFC-612) improves the reduction in motor nerve conduction velocity in spontaneously diabetic GK (Goto-Kakizaki) rats. Prostaglandins 1990; 40: 463–471. Medline
- 33Swett JE, Wikholm RP, Blanks RHI, Swett AL, Conley LC. Motoneurons of the rat sciatic nerve. Exp Neurol 1986; 93: 227–252. Medline
- 34Tackmann W, Lehmann HJ. Conduction of electrically elicited impulses in peripheral nerves of diabetic patients. Eur Neurol 1980; 19: 20–29. Medline
- 35Thomas PK, Lascelles RG. Schwann-cell abnormalities in diabetic neuropathy. Lancet 1965; 1: 1355–1357.
- 36Thomas PK, Tomlinson DR. Diabetic and hypoglycaemic neuropathy. In: PJ Dyck, PK Thomas, JW Griffin, PA Low, JF Poduslo, editors. Peripheral neuropathy. Philadelphia: WB Saunders; 1992. p 1219–1250.
- 37Tomlinson DR. The pharmacology of diabetic neuropathy. Diabet Metab Rev 1992; 7: 67–84.
- 38Tomlinson DR, Holmes PR, Mayer JH. Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus. Neurosci Lett 1982; 31: 189–193.
Medline
10.1016/0304-3940(82)90115-X Google Scholar
- 39Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes 1984; 33: 470–476. Medline
- 40Tomlinson DR, Robinson JP, Compton AM, Keen P. Essential fatty acid treatment—effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats. Diabetologia 1989; 32: 655–659. Medline
- 41Tze WJ, Sima AAF, Tai J. Effect of endocrine pancreas allotransplantation on diabetic nerve dysfunction. Metabolism 1985; 34: 721–725. Medline
- 42Wattig B, Warzok R, Thomas PK. Experimental diabetic neuropathy. Morphometric studies on the rat N. suralis in short-term streptozotocin-induced diabetes. Zentralbl Allg Pathol 1986; 131: 451–458. Medline
- 43Willars GB, Townsend J, Tomlinson DR, Compton AM, Churchill RD. Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil. Metabolism 1988; 37: 442–449.
Medline
10.1111/j.1460-9568.1995.tb00643.x Google Scholar
- 44Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 1990; 39: 690–696. Medline
- 45Yagihashi S, Kamijo M, Watanabe K. Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J Pathol 1990; 136: 1365–1373. Medline
- 46Young RJ, Macintyre CC, Martyn CN, Prescott RJ, Ewing DJ, Smith AF, Viberti G, Clarke BF. Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: associations with glycaemic control and microangiopathy (microvascular complications). Diabetologia 1986; 29: 156–161. Medline
- 47Yue DK, Hanwell MA, Satchell PM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 1982; 31: 789–794. Medline